India to Brazil: Amiodarone Export Trade Route

To import finished pharmaceutical formulations containing Amiodarone into Brazil, compliance with the Brazilian Health Regulatory Agency (ANVISA) regulations is mandatory. All pharmaceutical products, including imported ones, must obtain pre-market approval from ANVISA before commercialization. This approval process involves submitting a comprehensive dossier that adheres to ANVISA's specific requirements. While ANVISA's guidelines do not explicitly mandate the Common Technical Document (CTD) or electronic CTD (eCTD) format, the submission must encompass detailed information on the product's quality, safety, and efficacy.

The standard review timeline for marketing authorization applications is up to 365 days for regular submissions. For products granted priority review status, the timeline is reduced to 120 days. These timelines can be extended by a maximum of one-third of the original period. Upon approval, the marketing authorization is valid for ten years and can be renewed for equal and successive periods.

Regarding fees, ANVISA's fee structure varies based on the company's size and the type of application. Specific fee amounts are periodically updated and should be verified directly with ANVISA or through their official publications.

Additionally, ANVISA requires Good Manufacturing Practice (GMP) certification for all manufacturing facilities involved in producing the pharmaceutical product. This includes foreign manufacturers, such as those in India. ANVISA may conduct on-site inspections of these facilities to ensure compliance with Brazilian GMP standards. The certification process involves a thorough evaluation of the manufacturing processes, quality systems, and compliance with regulatory requirements.

Indian manufacturers exporting Amiodarone formulations to Brazil must obtain GMP certification from ANVISA. This certification, known as the Certificado de Boas Práticas de Fabricação (CBPF), confirms that the manufacturing facility complies with Brazilian GMP standards. The certification process typically involves an on-site inspection by ANVISA officials to assess the facility's adherence to quality and safety standards.

Several Indian pharmaceutical companies have successfully obtained or renewed their ANVISA GMP certifications in recent years. For instance, in July 2025, Naprod Life Sciences Pvt. Ltd. underwent a regulatory inspection of its Tarapur manufacturing facility, focusing on oncology injectable and oral solid dosage operations. The inspection concluded with no critical observations, leading to the renewal of their GMP certification in January 2026.

Similarly, Taj Pharma, a WHO-GMP certified Indian pharmaceutical manufacturer, supplies high-quality, ANVISA-compliant oral solid dosage and external preparations to Brazil, supporting both public tenders and private market distribution.

These examples underscore the importance of maintaining stringent quality standards and compliance with ANVISA regulations for Indian exporters aiming to access the Brazilian pharmaceutical market.

Between 2024 and 2026, ANVISA has implemented several regulatory changes impacting the importation of pharmaceutical products:

• Serialization and Track & Trace Requirements: In April 2022, ANVISA enforced the National Medicine Control System (SNCM), mandating unit-level serialization and track-and-trace capabilities for all pharmaceutical products. This system requires each product to have a GS1 2D DataMatrix code containing specific information, including the Global Trade Item Number (GTIN), ANVISA Medicine Registry Number, unique serial number, expiration date, and lot/batch number. Compliance with these requirements is essential for all pharmaceutical products imported into Brazil.

• GMP Certification Renewals: In July 2025, Naprod Life Sciences Pvt. Ltd. underwent a regulatory inspection of its Tarapur manufacturing facility, focusing on oncology injectable and oral solid dosage operations. The inspection concluded with no critical observations, leading to the renewal of their GMP certification in January 2026.

These developments highlight ANVISA's ongoing efforts to enhance the regulatory framework governing pharmaceutical imports, ensuring product quality and safety within the Brazilian market.

In 2025, Brazil accounted for 2.4% of the global Amiodarone market share, reflecting its significant demand for this antiarrhythmic medication. The country's large population, coupled with a public healthcare system that provides widespread access to essential medicines, drives this demand. The increasing prevalence of cardiovascular diseases, particularly arrhythmias, contributes to the sustained need for Amiodarone formulations. While Brazil has domestic pharmaceutical manufacturing capabilities, it continues to rely on imports to meet the full spectrum of its Amiodarone requirements.

Pharmaceutical products classified under HS code 30049099, including finished formulations containing Amiodarone, are subject to a 0% import duty rate in Brazil. This exemption aligns with Brazil's commitment to ensuring the availability of essential medicines. Additionally, there are no specific Free Trade Agreements (FTAs) between India and Brazil that alter this duty structure for pharmaceutical imports. The absence of anti-dumping duties further facilitates the importation of these products.

India is a major supplier of Amiodarone formulations to Brazil, with exports totaling $6.3 million USD across 103 shipments from six Indian manufacturers. This route represents 8.4% of India's total Amiodarone formulation exports, indicating a strong trade relationship. While specific data on other countries supplying Amiodarone to Brazil is not provided, India's significant share underscores its competitive position in the Brazilian market. The pricing of Indian Amiodarone formulations is competitive, contributing to their substantial presence in Brazil's pharmaceutical imports.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. This extensive manufacturing base includes a significant number of facilities dedicated to producing finished dosage forms containing Amiodarone, such as tablets and injections. As of November 2024, India had 134 facilities registered with the U.S. FDA for finished dosage forms, underscoring its substantial capacity in this sector.

The country's cost structure offers notable advantages. Efficient production processes, economies of scale, and a competitive labor market enable Indian manufacturers to produce high-quality Amiodarone formulations at lower costs compared to many other countries. Additionally, India's pharmaceutical industry boasts a significant number of WHO-GMP and FDA-approved facilities, ensuring compliance with stringent international quality standards.

When comparing Amiodarone formulation exports, India offers a compelling balance of cost and quality. Chinese manufacturers may provide lower-priced generic formulations; however, concerns about quality and regulatory compliance can arise. The European Union (EU) produces high-quality branded generics, but these often come at a premium price. Local Brazilian manufacturers may offer the advantage of proximity but might lack the production scale and cost efficiencies found in India.

In terms of regulatory acceptance, Indian pharmaceutical products are well-regarded in Brazil, with numerous Indian manufacturers holding approvals from ANVISA, Brazil's regulatory authority. This facilitates smoother import processes and market entry. India's track record for supply reliability is strong, supported by a robust manufacturing infrastructure and a history of fulfilling international orders consistently.

The India-Brazil supply chain for Amiodarone formulations is robust and reliable. Indian manufacturers possess substantial capacity for producing finished dosage forms, including advanced packaging and cold chain capabilities essential for maintaining product integrity during transit. While there have been occasional regulatory observations, leading manufacturers have demonstrated prompt corrective actions to maintain compliance. For instance, in May 2024, a routine GMP inspection by the U.S. FDA at Dr. Reddy's Laboratories' facilities resulted in a Form 483 with two observations, which were addressed promptly, leading to the closure of the audit by August 2024.

Top Indian formulation manufacturers continue to expand their capacities to meet growing global demand, ensuring a steady supply of Amiodarone formulations without significant constraints.

For Brazilian buyers sourcing Amiodarone formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that Indian manufacturers may have MOQs ranging from 5,000 to 50,000 units, depending on the product and manufacturer. Negotiating these quantities based on demand forecasts is essential.

• Payment Terms: Standard payment terms in India-Brazil pharmaceutical trade often include a 30% advance payment with the balance payable upon shipment or delivery. Establishing clear payment terms upfront is crucial.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits, verification of regulatory approvals (such as ANVISA certification), and assessment of the manufacturer's compliance history to ensure product quality and regulatory adherence.

• Regulatory Compliance: Ensure that the selected suppliers have a strong track record of compliance with international regulatory standards, including WHO-GMP and FDA approvals, to facilitate smoother importation and market entry in Brazil.

Cost Estimates and Timeline:

• Audit Visits to India:
• Cost: Approximately $10,000 to $15,000 USD per audit, covering travel, accommodation, and professional fees.
• Timeline: Planning and execution typically require 6 to 8 weeks, including scheduling, travel arrangements, on-site inspection, and reporting.

By adhering to this comprehensive supplier qualification framework, Brazilian pharmaceutical companies can ensure the procurement of high-quality Amiodarone formulations from Indian manufacturers, maintaining compliance with regulatory standards and safeguarding public health.